OXIS International senior management presented on Tuesday, May 18th at 2:50pm BST at the Rodman & Renshaw Annual Global Investment Conference. Chairman & CEO Tony Cataldo and President Bernie Landes unveiled the commercialization and rollout plan of OXIS' powerful patent and IP portfolio.

1. Advancing Oxidative
Stress Technology
OXIS INTERNATIONAL, INC.
Rodman and Renshaw, LLC
Global Investment Conference
London, UK // May 16–18, 2010

2. Advancing Oxidative
SAFE HARBOR STATEMENT Stress Technology
Except for the historical information contained herein, the matters discussed in this presentation include forward looking statements. Such statements
in this presentation, including future financings necessary for operations or acquisitions and future product launch dates are only predictions and reflect
current beliefs and expectations of the Company. Actual results may differ materially from those predicted in such forward looking statements due to
the risks and uncertainties inherent in the Company’s business, including, without limitation, risk and uncertainties in the obtaining possibly required
regulatory approvals, market acceptance of and continuing demand for the Company’s products, the impact of competitive products and pricing and
the Company’s ability to obtain additional financing to support its operations. We refer you to the risks and factors detailed from time to time in the
Company’s Annual Reports on Form 10-K and its Quarterly Reports on Form 10-Q. The Company undertakes no obligation to revise or update this
presentation to reflect circumstances after the date hereof.
THERAPEUTIC AND MANAGEMENT AND
Rodman and Renshaw, LLC | Global Investment Conference
THEN AND NOW SCIENTIFIC BACKGROUND CONSUMER PRODUCTS May 2010 1
CLINICAL PRODUCTS SCIENTIFIC ADVISORY BOARD

3. Then and Now

4. Advancing Oxidative
OXIS: FEBRUARY 2009 Stress Technology
• Pink Sheet Company
―Equity marketcap 3/31/09 = $1.9 Million
―60,000 average daily trading volume (US and Europe)
• No cash, many cash liabilities
• Limited management and Corporate Board, no functioning science committee
• Unable to meet SEC filing requirements
• No developed products
• No complete strategic plan
THERAPEUTIC AND MANAGEMENT AND
THEN AND NOW
THEN AND NOW SCIENTIFIC BACKGROUND CONSUMER PRODUCTS 3
CLINICAL PRODUCTS SCIENTIFIC ADVISORY BOARD

5. Advancing Oxidative
OXIS RECENT MILESTONE ACHIEVEMENTS Stress Technology
• Management • Financial Status
― Anthony Cataldo appointed Chairman & CEO ― $2 million capital raised in October 2009
― Bernie Landes appointed President ― Current liabilities and ongoing expenses at
― New CFO & Corporate Secretary manageable levels
― Additional members with strong experience in
marketing and distribution being recruited • Products
― Two nutraceutical products set to launch in summer
• Board of Directors - Revitalized with new members 2010 (Many more in pipeline)
and functioning committees ― Re-certifying FDA approved drug for
veterinary medicine
• Scientific Advisory Board Created
(With world class recognized experts) • SEC Filings – Up-to-date and complete
• Stock Trading
― Equity market cap 3/31/10= $13.7 Million
― Oxis.OB, OXI.PA
― Average daily trading volume over 1,500,000
shares per day (US and Europe)
THERAPEUTIC AND MANAGEMENT AND
THEN AND NOW
THEN AND NOW SCIENTIFIC BACKGROUND CONSUMER PRODUCTS 4
CLINICAL PRODUCTS SCIENTIFIC ADVISORY BOARD

6. Advancing Oxidative
OXIS TODAY Stress Technology
• Focusing on research, development and sale of products to combat oxidative stress –
common abnormality in which free radicals overwhelm antioxidant and other bodily defenses
and likely contribute to disease and aging
• Building on an estimated $75 million previously invested in IP development
• Developing multiple natural substance based products for substantial markets:
― Nutraceuticals
― Personal Care (including Cosmeceuticals)
― Animal Health (drugs and supplements)
― Therapeutic Compounds
• Emphasizing L-Ergothioneine (“ERGO”), a highly potent, patent protected, multifaceted antioxidant
• Leveraging multiple intellectual property holdings including: 12 patents and 7 patents pending in
oxidative stress technologies – continue to build IP with help of SAB
• Anticipating growth internally, through mergers and acquisitions, and in/out-licensing
THERAPEUTIC AND MANAGEMENT AND
THEN AND NOW
THEN AND NOW SCIENTIFIC BACKGROUND CONSUMER PRODUCTS 5
CLINICAL PRODUCTS SCIENTIFIC ADVISORY BOARD

7. OXIS ADDRESSES TWO MAJOR HEALTH ISSUES: Advancing Oxidative
OXIDATIVE STRESS AND INFLAMMATION Stress Technology
• Heart health (Inflammation in arteries)
• Brain health (Decline in cognitive ability, Alzheimer’s)
• Resistance against diseases (Maintain physiological homeostasis)
• Anti-aging/skin care (e.g., Skin protection/rejuvenation)
• Inflammation (Arthritis, joint pain)
• Detoxification (Liver)
• Blood sugar regulation (Protection against developing diabetes)
THERAPEUTIC AND MANAGEMENT AND
THEN AND NOW
THEN AND NOW SCIENTIFIC BACKGROUND CONSUMER PRODUCTS 6
CLINICAL PRODUCTS SCIENTIFIC ADVISORY BOARD

8. Advancing Oxidative
…WITH VERY LARGE MARKETS Stress Technology
OXIS CONSUMER PRODUCTS*
• Dietary supplements: $25 billion
• Functional foods and beverages: $37 billion
• Personal care (including cosmetics): $10 billion
• Companion animal supplements: $17 billion
OXIS THERAPEUTIC/CLINICAL PRODUCTS
• Veterinary health: $11 billion**
• Pharmaceutical compounds for target indications – several exceeding $100 million in size
*=Market size estimates for 2008 by Nutritional Business Journal
**=Market size estimate for 2008 by Vetnosis, Ltd.
THERAPEUTIC AND MANAGEMENT AND
THEN AND NOW
THEN AND NOW SCIENTIFIC BACKGROUND CONSUMER PRODUCTS 7
CLINICAL PRODUCTS SCIENTIFIC ADVISORY BOARD

9. Scientific Background

10. OXIDATIVE STRESS: CREATED WHEN FREE RADICALS Advancing Oxidative
EXCEED BODY’S NATURAL DEFENSES Stress Technology
FREE RADICALS
• An atom or group of atoms with unpaired electrons, creating Normal
unstable situations where cells and important organs may Oxygen
Atom
be damaged
• Generated normally as result of naturally occurring processes
when the body’s cells use oxygen to produce energy
Loss of
Electron
• Also result from other sources: air pollution, tobacco smoke,
ultraviolet rays, agricultural chemicals, psychological stress,
exhaustive exercise, drug intake and inflammation
Free
• Increases with aging and disease Radical
THERAPEUTIC AND MANAGEMENT AND
THEN AND NOW SCIENTIFIC BACKGROUND
SCIENTIFIC BACKGROUND CONSUMER PRODUCTS 9
CLINICAL PRODUCTS SCIENTIFIC ADVISORY BOARD

11. FREE RADICALS CAN CAUSE A VARIETY OF Advancing Oxidative
DESTRUCTIVE ACTIONS ON CELLS Stress Technology
Nucleus
Oxygen
Chromosome
Glucose
Oxygen radical
with unpaired electron
Superoxide
dismutase Energy
Damage to
mitochondrial
DNA
Hydrogen Peroxide
Motor Neuron Catalase
Damage to Oxygen
Nuclear DNA Water
THERAPEUTIC AND MANAGEMENT AND
THEN AND NOW SCIENTIFIC BACKGROUND
SCIENTIFIC BACKGROUND CONSUMER PRODUCTS 10
CLINICAL PRODUCTS SCIENTIFIC ADVISORY BOARD

12. Advancing Oxidative
OXIDATIVE STRESS Stress Technology
• Created by an imbalance in the physiologic ability (natural and ingested antioxidants)
to combat free radicals
• May be accelerated by excess alcohol and certain foods, certain pharmaceutical drugs, strenuous
exercise, inflammation and aging process
Disease Good Health Disease Good Health
Free Radicals Antioxidants Free Radicals Antioxidants
THERAPEUTIC AND MANAGEMENT AND
THEN AND NOW SCIENTIFIC BACKGROUND
SCIENTIFIC BACKGROUND CONSUMER PRODUCTS 11
CLINICAL PRODUCTS SCIENTIFIC ADVISORY BOARD

13. Advancing Oxidative
VULNERABLE BODY ELEMENTS/DISEASES Stress Technology
• Brain (Protein damage: Parkinson, Alzheimer, ALS)
• Eye (Cataract)
• Skin (Protein damage; Pre-Mature Aging)
• Heart (Lipid damage: Atherosclerosis)
• Lungs (Emphysema, COPD)
• Cancer (DNA damage)
• Reproductive System (Sperm protection)
• Various Inflammation Related (Arthritis)
THERAPEUTIC AND MANAGEMENT AND
THEN AND NOW SCIENTIFIC BACKGROUND
SCIENTIFIC BACKGROUND CONSUMER PRODUCTS 12
CLINICAL PRODUCTS SCIENTIFIC ADVISORY BOARD

14. Advancing Oxidative
ANTIOXIDANT DEFENSE SYSTEMS Stress Technology
• Internally produced antioxidant enzymes
―Superoxide dismutase (SOD)
―Catalase
―Glutathione Peroxidase (GPx)
• Ingested in diet and supplements:
―Vitamin A, C, E, beta-carotenes
―Proanthocyanins, anthocyanins, polyphenols, flavonoids, and metal chelators
• However, natural antioxidant systems can be overwhelmed creating Oxidative Stress
leading to disease states and premature aging
THERAPEUTIC AND MANAGEMENT AND
THEN AND NOW SCIENTIFIC BACKGROUND
SCIENTIFIC BACKGROUND CONSUMER PRODUCTS 13
CLINICAL PRODUCTS SCIENTIFIC ADVISORY BOARD

15. ERGOTHIONEINE (“ERGO”): Advancing Oxidative
PROPRIETARY SCIENCE BASE FOR INITIAL PRODUCTS Stress Technology
• Highly potent naturally occurring multifaceted • Significant well-documented benefits of ERGO
antioxidant - can’t be made internally by humans (based on over 100 research papers and studies):
― Conserves other antioxidants-
• Humans have special transporter system to Vitamin E and Glutathione (GSH)
concentrate ERGO in specific locations as
needed ― Increases respiration and oxidation of fat
― Reduces damage from ultraviolet radiation
• Found naturally in certain mushrooms, grapes,
― Protects mitochondria from damage
other foods, but not in quantities that can be
ingested in sufficient amounts to help humans ― Directly scavenges certain free radicals and
oxidants
• OXIS has proprietary technology to make ERGO ― Protects against damage from
in sufficient strength to be a dietary supplement neuro-toxins that maybe responsible for
and food/beverage ingredient creating cognitive decline
• Oxis has 3 patents and 2 patent pending ― Protects red blood cells
applications for ERGO (Several more
in development)
THERAPEUTIC AND MANAGEMENT AND
THEN AND NOW SCIENTIFIC BACKGROUND
SCIENTIFIC BACKGROUND CONSUMER PRODUCTS 14
CLINICAL PRODUCTS SCIENTIFIC ADVISORY BOARD

16. ERGO: A MULTI-FACETED, Advancing Oxidative
ANTI-INFLAMMATORY ANTIOXIDANT Stress Technology
Potential
ERGOTHIONEINE Pharmacogenomic
Benefit
Direct Antioxidant
Scavenging Action
Indirect Antioxidant
Stimulation of Antioxidant
Enzymes (GPx, GRx) Genetic and
Epigenetic Regulator
ROS Antiox Antioxidant Anti-Inflammatory
Aging Inflammation
OXIDATIVE STRESS
Infection Cancer
Neurodegenerative Alzheimer’s Diabetes, Atherosclerosis,
Metabolic Diseases
Diseases Parkinson’s Cardiovascular diseases
THERAPEUTIC AND MANAGEMENT AND
THEN AND NOW SCIENTIFIC BACKGROUND
SCIENTIFIC BACKGROUND CONSUMER PRODUCTS 15
CLINICAL PRODUCTS SCIENTIFIC ADVISORY BOARD

17. Consumer Products

18. Advancing Oxidative
CONSUMER PRODUCTS – TARGET SEGMENTS Stress Technology
NUTRITION AND WELLNESS
• Dietary Supplements
• Functional Foods
• Functional Beverages (e.g., energy drinks)
PERSONAL CARE
• Creams
• Cosmetics
• Hair care
THERAPEUTIC AND MANAGEMENT AND
THEN AND NOW SCIENTIFIC BACKGROUND CONSUMER PRODUCTS
CONSUMER PRODUCTS 17
CLINICAL PRODUCTS SCIENTIFIC ADVISORY BOARD

19. Advancing Oxidative
GO TO MARKET STRATEGIES – NUTRACEUTICALS Stress Technology
• Build direct to consumer sales relationships • Two product launches for Summer 2010
to maximize margins and repeat sales (Others to follow shortly afterwards)
―“Ergo-Pure” - ERGO in pure
• Create marketing alliances with key
thought leaders by product category form as a highly potent multifaceted
antioxidant
• Establish multiple channels:
―“Ergo-Plex” – ERGO plus other functional
―Multi-level marketing nutraceutical ingredients directed at Joint
―Internet sales Health/Pain relief.
―TV Infomercials • Actively exploring several joint venture and
―Long and short form radio infomercials acquisition opportunities
―Direct mail
―Traditional retail approaches
THERAPEUTIC AND MANAGEMENT AND
THEN AND NOW SCIENTIFIC BACKGROUND CONSUMER PRODUCTS
CONSUMER PRODUCTS 18
CLINICAL PRODUCTS SCIENTIFIC ADVISORY BOARD

20. GO TO MARKET STRATEGIES – Advancing Oxidative
PERSONAL CARE PRODUCTS Stress Technology
• Develop line of ERGO based products with mass marketer (Walmart, Walgreens, CVS, etc.)
• Develop line of products independently – go to market via direct mail, Internet, infomercials
or combination
• Develop strategic partnership with spa market participants and promote custom
developed products
• Develop separate line of personal care products for dermatology market and then also sell at
upscale retail channels such as Bloomingdales and Sephora
THERAPEUTIC AND MANAGEMENT AND
THEN AND NOW SCIENTIFIC BACKGROUND CONSUMER PRODUCTS
CONSUMER PRODUCTS 19
CLINICAL PRODUCTS SCIENTIFIC ADVISORY BOARD

21. Therapeutic and Clinical Products

22. THERAPEUTIC AND CLINICAL PRODUCTS – Advancing Oxidative
HIGH UPSIDE POTENTIAL Stress Technology
• Oxis has 9 patents and 5 patent pending applications that cover a number of current and potential
therapeutic and clinical applications
• Most indications for still available for out-licensing to biotech and pharmaceutical companies
• Anti-inflammatory indications seem most promising
• Several ERGO analogs (antioxidant mimics and variations of ERGO) also may have promise in
neurodegenerative (Alzheimer’s and Parkinson’s), diabetes and cardiovascular diseases
GAME PLAN:
• Initiate out-license program
• Add to IP based on relationships with leading researchers as guided by SAB
• JVs with third parties (Several under consideration)
THERAPEUTIC AND
THERAPEUTIC AND MANAGEMENT AND
THEN AND NOW SCIENTIFIC BACKGROUND CONSUMER PRODUCTS 21
CLINICAL PRODUCTS
CLINICAL PRODUCTS SCIENTIFIC ADVISORY BOARD

23. OXIS THERAPEUTIC AND CLINICAL PRODUCTS – Advancing Oxidative
IP PORTFOLIO HIGHLIGHTS Stress Technology
BXT-51072
―Action: Low weight anti-inflammatory glutathione peroxidase mimicking molecule that
metabolizes lipid peroxides
―Target Indications: cardiovascular and inflammatory bowel diseases
LIPID SOLUBLE ANTIOXIDANT COMPOUNDS
―Action: Natural cell penetrating potent (20-40X) agent that mimics Vitamin E
―Target Indications: neurodegenerative (Alzheimer’s and Parkinson’s) and
cardiovascular diseases
SUPEROXIDE DISMUTASE (“SOD”) RELATED COMPOUNDS
―Action: Naturally occurring ubiquitous enzyme that reduces superoxide (a pivotal free radical)
found in all living organisms
―Target Indications: Inflammatory joint disease and prevention of radiation toxicity
THERAPEUTIC AND
THERAPEUTIC AND MANAGEMENT AND
THEN AND NOW SCIENTIFIC BACKGROUND CONSUMER PRODUCTS 22
CLINICAL PRODUCTS
CLINICAL PRODUCTS SCIENTIFIC ADVISORY BOARD

24. THERAPEUTIC AND CLINICAL PRODUCTS – Advancing Oxidative
FDA APPROVED DRUG FOR ANIMALS Stress Technology
• Palosein™ - anti-inflammatory form of SOD (Orgotein)
• Derived from bovine liver
• Previously sold by Oxis
• Currently re-certifying manufacturing process to resume sales
• In discussions with potential distribution partners
THERAPEUTIC AND
THERAPEUTIC AND MANAGEMENT AND
THEN AND NOW SCIENTIFIC BACKGROUND CONSUMER PRODUCTS 23
CLINICAL PRODUCTS
CLINICAL PRODUCTS SCIENTIFIC ADVISORY BOARD

25. Management and Scientific Advisory Board

26. Advancing Oxidative
MANAGEMENT TEAM Stress Technology
ANTHONY CATALDO
• Overall management, financings, investor and public relations
CHAIRMAN & CEO, • Multiple times public company CEO or Chairman with life science focus (Calypte, Senetek)
DIRECTOR
• Significant public company investor relations and financing experience
• Overall product/market strategy, mergers, acquisitions, alliances nutraceutical and cosmeceutical
product development and management
BERNIE LANDES
PRESIDENT • Multiple top management and advisory roles in nutrition, natural foods, supplements, skin care
• Experience at Suracell, Monavie, Zila, Paracelsian, Alacer, Health Valley
• Overall responsibility for financial management and reporting
MICHAEL HANDELMAN
CFO & TREASURER
• Multiple times CFO including LA Kings Hockey Team and several start-ups
• CPA
• Corporate Governance, Administration, Special Projects
GARY POST
SECRETARY &
• Multiple interim public and private company Board Member/CEO/COO –
initiated Oxis strategy transition
DIRECTOR
• Investing and advising with Ambient Advisors, McKinsey, Kidder Peabody, Drexel Burnham
THERAPEUTIC AND MANAGEMENT AND
THEN AND NOW SCIENTIFIC BACKGROUND CONSUMER PRODUCTS 25
CLINICAL PRODUCTS SCIENTIFIC ADVISORY BOARD
SCIENTIFIC ADVISORY BOARD

27. Advancing Oxidative
SCIENTIFIC ADVISORY BOARD Stress Technology
A STRONG SAB IS ACTIVELY ASSISTING WITH KEY CONTRIBUTIONS:
• Participating in product development
• Evaluating and contributing to additional IP opportunities
• Evaluating merger, in and out-license opportunities
• Assisting in communicating the Oxis science story to investors
THERAPEUTIC AND MANAGEMENT AND
THEN AND NOW SCIENTIFIC BACKGROUND CONSUMER PRODUCTS 26
CLINICAL PRODUCTS SCIENTIFIC ADVISORY BOARD
SCIENTIFIC ADVISORY BOARD

28. Advancing Oxidative
INITIAL MEMBERS OF SAB Stress Technology
OKEZIE I. AROUMA, JOHN E. REPINE, M.D.
BSc, MBA, PhD, MSc, DSc
• Waring Professor of Medicine, Pediatrics
• Professor of Pharmaceutical and Surgery at University of Colorado
and Biomedical Sciences, and Director of Webb-Waring Center
Touro College of Pharmacy, NYC
• Pulmonary/Critical Care Specialist
• Biochemist, world expert and and expert in antioxidant and
leading researcher re: Ergothioneine inflammatory research
and Oxidative Stress
• Author of over 300 peer review articles
• Author of 10 books and 250 peer review and 14 patent applications
papers focused on oxidative stress, dietary
antioxidants and diseases of overt
inflammation, two patent applications
Other candidates under consideration for the SAB have complementary
specialties in science and product development
THERAPEUTIC AND MANAGEMENT AND
THEN AND NOW SCIENTIFIC BACKGROUND CONSUMER PRODUCTS 27
CLINICAL PRODUCTS SCIENTIFIC ADVISORY BOARD
SCIENTIFIC ADVISORY BOARD

29. Summary

30. Advancing Oxidative
MARKET SNAPSHOT (April 30, 2010) Stress Technology
COMMON STOCK TICKER: (OXIS.OB) (OXI.PA)
STOCK PRICE: $0.19
52 WEEK RANGE: $0.04 – $0.61
SHARES OUTSTANDING: 102.5 million
MARKET CAPITALIZATION: $ 19.5 million
THERAPEUTIC AND MANAGEMENT AND
Rodman and Renshaw, LLC | Global Investment Conference
THEN AND NOW SCIENTIFIC BACKGROUND CONSUMER PRODUCTS May 2010 29
CLINICAL PRODUCTS SCIENTIFIC ADVISORY BOARD

31. Advancing Oxidative
KEY POINTS Stress Technology
• Large potential markets for unique products, especially incorporating ERGO
• Strong IP position
• Diversified strategies for growth
• Highly qualified Management and SAB team
THERAPEUTIC AND MANAGEMENT AND
MANAGEMENT AND
Rodman and Renshaw, LLC | Global Investment Conference
THEN AND NOW SCIENTIFIC BACKGROUND CONSUMER PRODUCTS May 2010 30
CLINICAL PRODUCTS SCIENTIFIC ADVISORY BOARD

32. Thank You